{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:08:14Z","timestamp":1784308094368,"version":"3.55.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"DOI":"10.1093\/bjd\/ljag189","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:02:36Z","timestamp":1778760156000},"page":"207-208","source":"Crossref","is-referenced-by-count":0,"title":["Patient phenotyping to guide therapeutic strategies in\u00a0bullous pemphigoid: towards personalized medicine in autoimmune bullous diseases"],"prefix":"10.1093","volume":"195","author":[{"given":"Roberto","family":"Maglie","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026071712545715900_ljag189-B1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/bjd\/ljae219","article-title":"Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids","volume":"191","author":"Kridin","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026071712545715900_ljag189-B2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2\u2005K \u00adguidelines for the management of bullous pemphigoid \u00adinitiated\u00a0by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026071712545715900_ljag189-B3","doi-asserted-by":"crossref","first-page":"1128154","DOI":"10.3389\/fmed.2023.1128154","article-title":"The cytokine milieu of bullous pemphigoid: current and novel therapeutic targets","volume":"10","author":"Maglie","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026071712545715900_ljag189-B4","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1038\/s41467-025-62495-2","article-title":"IgG autoantibodies in bullous pemphigoid induce a pathogenic MyD88-dependent pro-inflammatory response in keratinocytes","volume":"16","author":"Bao","year":"2025","journal-title":"Nat Commun"},{"key":"2026071712545715900_ljag189-B5","doi-asserted-by":"crossref","first-page":"973702","DOI":"10.3389\/fimmu.2022.973702","article-title":"The relevance of complement in pemphigoid diseases: a critical appraisal","volume":"13","author":"Papara","year":"2022","journal-title":"Front Immunol"},{"key":"2026071712545715900_ljag189-B6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14728214.2025.2555080","article-title":"Emerging drugs for the treatment of bullous pemphigoid: what\u2019s new on the horizon?","volume":"30","author":"Olbrich","year":"2025","journal-title":"Expert Opin Emerg Drugs"},{"key":"2026071712545715900_ljag189-B7","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljag156","article-title":"A clinically actionable stratification of bullous pemphigoid using a disease activity score reveals a targetable inflammatory endotype","volume":"195","author":"Cao","year":"2026","journal-title":"Br J Dermatol"},{"key":"2026071712545715900_ljag189-B8","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","article-title":"Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"2026071712545715900_ljag189-B9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/bjd\/ljaf035","article-title":"Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case series","volume":"192","author":"Maglie","year":"2025","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag189\/68295672\/ljag189.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/2\/207\/68295672\/ljag189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/2\/207\/68295672\/ljag189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:55:03Z","timestamp":1784307303000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/195\/2\/207\/8679195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,4]]},"published-print":{"date-parts":[[2026,7,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag189","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,4]]}}}